Prevent Chlamydia News Today

Phase 2B/3 AMPREVENCE Clinical Trial Concluded with Women Experiencing a 50 Percent Risk Reduction in Chlamydia Trachomatis (chlamydia) and a 78 Percent Risk...

--Evofem Biosciences, Inc., today presented data at the Academy of Managed Care Pharmacy annual meeting showing EVO100 provided a significant decrease in gonorrhea and chlamydia infections in women as well as additional patient health outcomes related to satisfaction with use of the investigational product. "Findings from these analyses demonstrate the...